European Archives of Oto-Rhino-Laryngology

, Volume 265, Issue 2, pp 139–145 | Cite as

Treating common ear problems in pregnancy: what is safe?

  • Petros V. Vlastarakos
  • Thomas P. Nikolopoulos
  • Leonidas Manolopoulos
  • Eleftherios Ferekidis
  • George Kreatsas
Review Article


In everyday practise, more than 80% of pregnant women receive one at least medication, often for ENT causes. The aim of the present paper is to review the literature on safety and administration of medical treatment for ear diseases, in pregnant women. The literature review includes Medline and database sources. Electronic links, related books and written guidelines were also included. The study selection was as follows: controlled clinical trials, prospective trials, case-control studies, laboratory studies, clinical reviews, systematic reviews, metanalyses, and case reports. The following drugs are considered relatively safe: beta-lactam antibiotics (with dose adjustment), macrolides (although the use of erythromycin and clarithromycin carries a certain risk), and acyclovir. Non-selective NSAIDs (until the 32nd week), nasal decongestants (with caution and up to 7 days), intranasal corticosteroids, with budesonide as the treatment of choice, first generation antihistamines, or cetirizine (third trimester) and loratadine (second and third trimester) from the second generation, H2 receptor antagonists (except nizatidine) and proton pump inhibitors (except omeprazole), can be used to relieve patients from the related symptoms. Meclizine and dimenhydrinate, as antiemetics in vertigo attacks; metoclopramide, vitamin B6 and ginger rhizome, alternatively. Low-dose diazepam and diuretics in severe cases of Meniere’s disease (with caution). Systemic administration of prednisone and prednisolone can be considered in selected cases. By contrast, selective COX-2 inhibitors, betahistine and vasodilating agents are contraindicated in pregnancy. Since otologic and neurotologic manifestations during pregnancy tend to seriously affect the quality of life of the expectant mothers, ENT surgeons should familiarise themselves with the basic guidelines and safety precautions for any related medication, in order to provide appropriate treatment.


Pregnancy Ear Drugs Safety Teratogenicity 


  1. 1.
    Holt GR, Mabry RL (1983) ENT medications in pregnancy. Otolaryngol Head Neck Surg 91:338–41PubMedGoogle Scholar
  2. 2.
    Abrams RS (1990) Will it hurt the baby? The safe use of medications during pregnancy and breastfeeding. Addison-Wesley, Reading, pp 1–5Google Scholar
  3. 3.
    Rubin PC (1986) Prescribing in pregnancy. General principles. BMJ 293:1415–1417PubMedGoogle Scholar
  4. 4.
    Moore KL (1988) The developing human: clinically oriented embryology, 4th edn. W.B. Saunders, Philadelphia, p 131Google Scholar
  5. 5.
    Schatz M (1997) Asthma treatment during pregnancy. What can be safely taken? Drug Saf 16(5):342–350PubMedCrossRefGoogle Scholar
  6. 6.
    Ekelund H, Kullander S, Kallen B (1970) Major and minor malformations in newborns and infants up to one year of age. Acta Paediatr Scand 59:297–302PubMedCrossRefGoogle Scholar
  7. 7.
    Ash P, Vennart J, Carter CO (1977) The incidence of hereditary disease in man. J Med Genet 14:305PubMedGoogle Scholar
  8. 8.
    Sa del Fiol F, Gerenutti M, Groppo FC (2005) Antibiotics and pregnancy. Pharmazie 60(7):483–493Google Scholar
  9. 9.
    Goodnight WH, Soper DE (2005) Pneumonia in pregnancy. Crit Care Med 33(10 Suppl):S390–S397PubMedCrossRefGoogle Scholar
  10. 10.
    Lim WS, Macfarlane JT, Colthorpe CL (2003) Treatment of community-acquired lower respiratory tract infections during pregnancy. Am J Respir Med 2(3):221–233PubMedGoogle Scholar
  11. 11.
    Miller EL (2002) The penicillins: a review and update. J Midwifery Womens Health 47(6):426–434PubMedCrossRefGoogle Scholar
  12. 12.
    Christensen B (2000) Which antibiotics are appropriate for treating bacteriuria in pregnancy? J Antimicrob Chemother 46(Suppl 1):29–34 discussion 63–65CrossRefGoogle Scholar
  13. 13.
    Rouveix B, Levacher M, Giroud JP (1999) Drugs for respiratory tropism and pregnancy (article in French). Rev Pneumol Clin 55(5):338–343PubMedGoogle Scholar
  14. 14.
    Garland SM, O’Reilly MA (1995) The risks and benefits of antimicrobial therapy in pregnancy Drug Saf 13(3):188–205PubMedGoogle Scholar
  15. 15.
    Friese K (1993) Antibiotic therapy in pregnancy (article in German). Immun Infekt 21(4):111–114PubMedGoogle Scholar
  16. 16.
    Leophonte P (1988) Antibiotics during pregnancy and breast feeding: consequences for the treatment of respiratory infections. Rev Mal Respir 5(3):293–298PubMedGoogle Scholar
  17. 17.
    Ellegard EK (2004) Clinical and pathogenetic characteristics of pregnancy rhinitis. Clin Rev Allergy Immunol 26(3):149–159PubMedCrossRefGoogle Scholar
  18. 18.
    Heikkila A, Erkkola R (1994) Review of beta-lactam antibiotics in pregnancy. The need for adjustment of dosage schedules. Clin Pharmacokinet 27(1):49–62PubMedGoogle Scholar
  19. 19.
    Mucklow JC (1986) The fate of drugs in pregnancy. Clin Obstet Gynaecol 13(2):161–175PubMedGoogle Scholar
  20. 20.
    Brocklehurst P (2002) Antibiotics for gonorrhoea in pregnancy. Cochrane Database Syst Rev (2):CD000098Google Scholar
  21. 21.
    Di Lorenzo G, Mansueto P, Melluso M, Purello D’Ambrosio F, Putignano E, Barbagallo Sangiorgi G (1994) Allergy in pregnancy (article in Italian). Clin Ter 145(9):223–229PubMedGoogle Scholar
  22. 22.
    Sarkar M, Woodland C, Koren G, Einarson AR (2006) Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy Childbirth 6(5):18PubMedCrossRefGoogle Scholar
  23. 23.
    Källén BA, Otterblad Olausson P, Danielsson BR (2005) Is erythromycin therapy teratogenic in humans? Reprod Toxicol 20(2):209–214PubMedGoogle Scholar
  24. 24.
    Källén BA, Otterblad Olausson P (2003) Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 17(3):255–261PubMedCrossRefGoogle Scholar
  25. 25.
    Czeizel A, Rockenbauer M, Sørensen HT, Olsen J (1999) A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol 13(6):531–536PubMedCrossRefGoogle Scholar
  26. 26.
    Louik C, Werler MM, Mitchell AA (2002) Erythromycin use during pregnancy in relation to pyloric stenosis. Am J Obstet Gynecol 186(2):288–290PubMedCrossRefGoogle Scholar
  27. 27.
    Amsden GW (1996) Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther 18(1):56–72 discussion 55PubMedCrossRefGoogle Scholar
  28. 28.
    Chun JY, Han JY, Ahn HK, Choi JS, Koong MK, Nava-Ocampo AA, Koren G (2006) Fetal outcome following roxithromycin exposure in early pregnancy. J Matern Fetal Neonatal Med 19(3):189–92PubMedCrossRefGoogle Scholar
  29. 29.
    Bogacka E (1999) Decongestants in treatment of nasal obstruction (article in Polish/abstract). Otolaryngol Pol 53(3):347–352PubMedGoogle Scholar
  30. 30.
    Mazzotta P, Loebstein R, Koren G (1999) Treating allergic rhinitis in pregnancy. Safety considerations. Drug Saf 20(4):361–375PubMedCrossRefGoogle Scholar
  31. 31.
    Naclerio RM (1998) Optimizing treatment options. Clin Exp Allergy 28(Suppl 6):54–59PubMedCrossRefGoogle Scholar
  32. 32.
    Gilbert C, Mazzotta P, Loebstein R, Koren G (2005) Fetal safety of drugs used in the treatment of allergic rhinitis: a critical review. Drug Saf 28(8):707–719PubMedCrossRefGoogle Scholar
  33. 33.
    Keles N (2004) Treatment of allergic rhinitis during pregnancy. Am J Rhinol 18(1):23–28PubMedGoogle Scholar
  34. 34.
    Schatz M, Zeiger RS, Harden K, Hoffman CC, Chilingar L, Petitti D (1997) The safety of asthma and allergy medications during pregnancy. J Allergy Clin Immunol 100(3):301–306PubMedCrossRefGoogle Scholar
  35. 35.
    Demoly P, Piette V, Daures JP (2003) Treatment of allergic rhinitis during pregnancy (article in French). Drugs 63(17):1813–1820PubMedCrossRefGoogle Scholar
  36. 36.
    Gilbert-Barness E, Drut RM (2000) Association of sympathomimetic drugs with malformations. Vet Hum Toxicol 42(3):168–171PubMedGoogle Scholar
  37. 37.
    Ugen KE, Scott WJ Jr (1987) Reduction of uterine blood flow by phenylephrine, an alpha-adrenergic agonist, in the day 11 pregnant rat: relationship to potentiation of acetazolamide teratogenesis. Teratology 36(1):133–141PubMedCrossRefGoogle Scholar
  38. 38.
    No authors listed (2000) The use of newer asthma and allergy medications during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI). Ann Allergy Asthma Immunol 84(5):475–480Google Scholar
  39. 39.
    No authors listed (2004) Gastroschisis and pseudoephedrine during pregnancy. Prescrire Int 13(72):141–143Google Scholar
  40. 40.
    Werler MM (2006) Teratogen update: pseudoephedrine. Birth Defects Res A Clin Mol Teratol 76(6):445–452PubMedCrossRefGoogle Scholar
  41. 41.
    Torfs CP, Katz EA, Bateson TF, Lam PK, Curry CJ (1996) Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 54(2):84–92PubMedCrossRefGoogle Scholar
  42. 42.
    Werler MM, Mitchell AA, Shapiro S (1992) First trimester maternal medication use in relation to gastroschisis. Teratology 45(4):361–367PubMedCrossRefGoogle Scholar
  43. 43.
    Blaiss MS (2003) Food, drug administration (US); ACAAI–ACOG (American College of Allergy, Asthma, and Immunology and American College of Obstetricians and Gynecologists). Management of rhinitis and asthma in pregnancy. Ann Allergy Asthma Immunol 90(6 Suppl 3):16–22PubMedCrossRefGoogle Scholar
  44. 44.
    Gluck PA, Gluck JC (2005) A review of pregnancy outcomes after exposure to orally inhaled or intranasal budesonide. Curr Med Res Opin 21(7):1075–1084PubMedCrossRefGoogle Scholar
  45. 45.
    Osur SL (2005) The management of asthma and rhinitis during pregnancy. J Womens Health (Larchmt) 14(3):263–276Google Scholar
  46. 46.
    Gani F, Braida A, Lombardi C, Del Giudice A, Senna GE, Passalacqua G (2003) Rhinitis in pregnancy. Allerg Immunol (Paris) 35(8):306–313Google Scholar
  47. 47.
    Paris-Kohler A, Megret-Gabeaud ML, Fabre C, Mares P, Vincent D (2001) The allergic pregnant woman (article in French). Allerg Immunol (Paris) 33(10):399–403Google Scholar
  48. 48.
    Bothamley G (2001) Drug treatment for tuberculosis during pregnancy: safety considerations. Drug Saf 24(7):553–565PubMedCrossRefGoogle Scholar
  49. 49.
    Shehata H, Nelson-Piercy C (2001) Drugs to avoid. Best Pract Res Clin Obstet Gynaecol 15(6):971–986PubMedCrossRefGoogle Scholar
  50. 50.
    Ostensen ME, Skomsvoll JF (2004) Anti-inflammatory pharmacotherapy during pregnancy. Expert Opin Pharmacother 5(3):571–80PubMedCrossRefGoogle Scholar
  51. 51.
    Fardet L, Nizard J, Genereau T (2002) Non-selective and selective non-steroidal anti-inflammatory drugs, administration in pregnancy and breast feeding (article in French). Presse Med 31(31):1462–1468PubMedGoogle Scholar
  52. 52.
    Burdan F, Belzek A (2001) Current opinions on embryotoxic and teratogenic effects of ibuprofen (article in Polish/abstract). Pol Merkuriusz Lek 11(63):266–270Google Scholar
  53. 53.
    Ostensen M (1998) Nonsteroidal anti-inflammatory drugs during pregnancy. Scand J Rheumatol Suppl 107:128–132PubMedGoogle Scholar
  54. 54.
    Ostensen M, Ramsey-Goldman R (1998) Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? Drug Saf 19(5):389–410PubMedCrossRefGoogle Scholar
  55. 55.
    Ostensen M (1994) Optimisation of antirheumatic drug treatment in pregnancy. Clin Pharmacokinet 27(6):486–503Google Scholar
  56. 56.
    Schoenfeld A, Bar Y, Merlob P, Ovadia Y (1992) NSAIDs: maternal and fetal considerations. Am J Reprod Immunol 28(3–4):141–147PubMedGoogle Scholar
  57. 57.
    Burdan F (2001) Prenatal effects of acetylsalicylic acid (article in Polish/abstract). Pol Merkuriusz Lek 11(62):182–186Google Scholar
  58. 58.
    De Santis M, Carducci B, Cavaliere AF, De Santis L, Straface G, Caruso A (2001) Drug-induced congenital defects: strategies to reduce the incidence. Drug Saf 24(12):889–901PubMedCrossRefGoogle Scholar
  59. 59.
    Janssen NM, Genta MS (2000) The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 160(5):610–619PubMedCrossRefGoogle Scholar
  60. 60.
    Gran JT, Ostensen M (1998) Spondyloarthritides in females. Baillieres Clin Rheumatol 12(4):695–715PubMedCrossRefGoogle Scholar
  61. 61.
    Pfaffenrath V, Rehm M (1998) Migraine in pregnancy: what are the safest treatment options? Drug Saf 19(5):383–388PubMedCrossRefGoogle Scholar
  62. 62.
    Werler MM, Sheehan JE, Mitchell AA (2002) Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 155(1):26–31PubMedCrossRefGoogle Scholar
  63. 63.
    Ericson A, Källén BA (2001) Nonsteroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol 15(4):371–375PubMedCrossRefGoogle Scholar
  64. 64.
    Yodfat Y (2004) Is there a future for COX-2 inhibitors? (article in Hebrew/abstract) Harefuah 143(11):820–824 837PubMedGoogle Scholar
  65. 65.
    Chan VS (2004) A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy. Drug Saf 27(7):421–426PubMedCrossRefGoogle Scholar
  66. 66.
    Bannwarth B, Pehourcq F (2003) Pharmacologic basis for using paracetamol: pharmacokinetic and pharmacodynamic issues. Drugs 63(2):5–13PubMedCrossRefGoogle Scholar
  67. 67.
    Berkovitch M, Diav-Citrin O, Greenberg R, Cohen M, Bulkowstein M, Shechtman S, Bortnik O, Arnon J, Ornoy A (2004) First-trimester exposure to amoxycillin/clavulanic acid: a prospective, controlled study. Br J Clin Pharmacol 58(3):298–302PubMedCrossRefGoogle Scholar
  68. 68.
    Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J (2001) Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case-control teratologic study. Eur J Obstet Gynecol Reprod Biol 97(2):188–192PubMedCrossRefGoogle Scholar
  69. 69.
    Fairbanks DNF (2003) Pocket guide to antimicrobial therapy in otolaryngology-head and neck surgery, 11th edn. American Academy of Otolaryngology-Head and Neck Surgery FoundationGoogle Scholar
  70. 70.
    Loh KY, Sivalingam N (2005) Understanding hyperemesis gravidarum. Med J Malaysia 60(3):394–399. Quiz 400PubMedGoogle Scholar
  71. 71.
    Nelson-Piercy C (1998) Treatment of nausea and vomiting in pregnancy. When should it be treated and what can be safely taken? Drug Saf 19(2):155–164PubMedCrossRefGoogle Scholar
  72. 72.
    Magee LA, Mazzotta P, Koren G (2002) Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol 186(5 Suppl Understanding):S256–S261PubMedCrossRefGoogle Scholar
  73. 73.
    Flake ZA, Scalley RD, Bailey AG (2004) Practical selection of antiemetics. Am Fam Physician 69(5):1169–1174PubMedGoogle Scholar
  74. 74.
    Leathem AM (1986) Safety and efficacy of antiemetics used to treat nausea and vomiting in pregnancy. Clin Pharm 5(8):660–668PubMedGoogle Scholar
  75. 75.
    Schroder O, Stein J (2002) Vomiting in pregnancy. When is it more than only a bothersome nuisance? (article in German). MMW Fortschr Med 144(50):32–34PubMedGoogle Scholar
  76. 76.
    Jewell D, Young G (2003) Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev (4):CD000145Google Scholar
  77. 77.
    Langner E, Greifenberg S, Gruenwald J (1998) Ginger: history and use. Adv Ther 15(1):25–44PubMedGoogle Scholar
  78. 78.
    Borrelli F, Capasso R, Aviello G, Pittler MH, Izzo AA (2005) Effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and vomiting. Obstet Gynecol 105(4):849–856PubMedGoogle Scholar
  79. 79.
    Betz O, Kranke P, Geldner G, Wulf H, Eberhart LH (2005) Is ginger a clinically relevant antiemetic? A systematic review of randomized controlled trials (article in German). Forsch Komplementarmed Klass Naturheilkd 12(1):14–23PubMedCrossRefGoogle Scholar
  80. 80.
    Bryer E (2005) A literature review of the effectiveness of ginger in alleviating mild-to-moderate nausea and vomiting of pregnancy. J Midwifery Womens Health 50(1):1–3CrossRefGoogle Scholar
  81. 81.
  82. 82.
    Uchide K, Suzuki N, Takiguchi T, Terada S, Inoue M (1997) The possible effect of pregnancy on Meniere’s disease. ORL J Otorhinolaryngol Relat Spec 59(5):292–295PubMedGoogle Scholar
  83. 83.
    Kyle PM, Redman CW (1992) Comparative risk-benefit assessment of drugs used in the management of hypertension in pregnancy. Drug Saf 7(3):223–234PubMedCrossRefGoogle Scholar
  84. 84.
    Hansen L, Sobol S, Abelson T (1986) Otolalyngologic manifestations of pregnancy. J Fam Pract 23(2):151–155PubMedGoogle Scholar
  85. 85.
    Huynh-Do U, Frey FJ (2000) Potential dangers of diuretics (article in German). Ther Umsch 57(6):408–411PubMedCrossRefGoogle Scholar
  86. 86.
    Oren D, Nulman I, Makhija M, Ito S, Koren G (2004) Using corticosteroids during pregnancy. Are topical, inhaled, or systemic agents associated with risk? Can Fam Physician 50:1083–1085PubMedGoogle Scholar
  87. 87.
    Schatz M (2001) The efficacy and safety of asthma medications during pregnancy. Semin Perinatol 25(3):145–152PubMedCrossRefGoogle Scholar
  88. 88.
    Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, Friesen MH, Jacobson S, Kasapinovic S, Chang D, Diav-Citrin O, Chitayat D, Nulman I, Einarson TR, Koren G (2000) Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62(6):385–392PubMedCrossRefGoogle Scholar
  89. 89.
    Ambro BT, Scheid SC, Pribitkin EA (2003) Prescribing guidelines for ENT medications during pregnancy. ENT J 82(8):565–568Google Scholar
  90. 90.
    Lockshin MD, Sammaritano LR (1998) Corticosteroids during pregnancy. Scand J Rheumatol Suppl 107:136–138PubMedGoogle Scholar
  91. 91.
    Guillonneau M, Jacqz-Aigrain E (1996) Maternal corticotherapy. Pharmacology and effect on the fetus (article in French). J Gynecol Obstet Biol Reprod (Paris) 25(2):160–167Google Scholar
  92. 92.
    Garbis H, Elefant E, Diav-Citrin O, Schaefer C, Vial T, Clementi M, Valti E, McElhatton P, Smorlesi C, Rodriguez EP, Robert-Gnansia E, Merlob P, Peiker G, Pexieder T, Schueler L, Ritvanen A, Mathieu-Nolf M (2005) Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services. Reprod Toxicol 19(4):453–458PubMedCrossRefGoogle Scholar
  93. 93.
    Cappell MS (2003) Gastric and duodenal ulcers during pregnancy. Gastroenterol Clin North Am 32(1):263–308PubMedCrossRefGoogle Scholar
  94. 94.
    Charan M, Katz PO (2001) Gastroesophageal reflux disease in pregnancy. Curr Treat Options Gastroenterol 4(1):73–81PubMedCrossRefGoogle Scholar
  95. 95.
    Michaletz-Onody PA (1992) Peptic ulcer disease in pregnancy. Gastroenterol Clin North Am 21(4):817–826PubMedGoogle Scholar
  96. 96.
    Kyle PM (2006) Drugs and the fetus. Curr Opin Obstet Gynecol 18(2):93–99PubMedCrossRefGoogle Scholar
  97. 97.
    Diav-Citrin O, Arnon J, Shechtman S, Schaefer C, van Tonningen MR, Clementi M, De Santis M, Robert-Gnansia E, Valti E, Malm H, Ornoy A (2005) The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther 21(3):269–275PubMedCrossRefGoogle Scholar
  98. 98.
    Richter JE (2003) Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin North Am 32(1):235–261PubMedCrossRefGoogle Scholar
  99. 99.
    Nikfar S, Abdollahi M, Moretti ME, Magee LA, Koren G (2002) Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci 47(7):1526–1529PubMedCrossRefGoogle Scholar
  100. 100.
    Nielsen GL, Sorensen HT, Thulstrup AM, Tage-Jensen U, Olesen C, Ekbom A (1999) The safety of proton pump inhibitors in pregnancy. Aliment Pharmacol Ther 13(8):1085–1089PubMedCrossRefGoogle Scholar
  101. 101.
    Nava-Ocampo AA, Velázquez-Armenta EY, Han JY, Koren G (2006) Use of proton pump inhibitors during pregnancy and breastfeeding. Can Fam Physician 52:853–854PubMedGoogle Scholar
  102. 102.
    Källén BA (2001) Use of omeprazole during pregnancy-no hazard demonstrated in 955 infants exposed during pregnancy. Eur J Obstet Gynecol Reprod Biol 96(1):63–68PubMedCrossRefGoogle Scholar
  103. 103.
    Tyring SK, Baker D, Snowden W (2002) Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years’ experience with acyclovir. J Infect Dis 186(Suppl 1):S40–S46PubMedCrossRefGoogle Scholar
  104. 104.
    Haddad J, Messer J, Willard D, Ritter J (1989) Acyclovir and pregnancy: current aspects (article in French). J Gynecol Obstet Biol Reprod (Paris) 18(5):679–683Google Scholar
  105. 105.
    May M (1980) Bell’s palsy: diagnosis, prognosis and treatment. Surg Rounds 13(1):38–48Google Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Petros V. Vlastarakos
    • 1
    • 3
  • Thomas P. Nikolopoulos
    • 1
  • Leonidas Manolopoulos
    • 1
  • Eleftherios Ferekidis
    • 1
  • George Kreatsas
    • 2
  1. 1.ENT DepartmentHippokrateion General Hospital of AthensAthensGreece
  2. 2.OBG DepartmentAreteion University HospitalAthensGreece
  3. 3.Glyfada-AthensGreece

Personalised recommendations